MARK FRAZEE: Open Payments
NPI 1295999001 · INDIANAPOLIS, IN. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$337 in 12 payments from 11 companies in 2025. Trend: 2023 $178 · 2024 $200 · 2025 $337
Food & beverage: $337
| Company | Payments | Amount |
|---|---|---|
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | 1 | $124 |
| Actelion Pharmaceuticals US, Inc. | 2 | $32 |
| Verona Pharma, Inc. | 1 | $30 |
| GENZYME CORPORATION | 1 | $26 |
| Viatris Specialty LLC | 1 | $26 |
| Bayer Healthcare Pharmaceuticals Inc. | 1 | $19 |
| Electromed, Inc. | 1 | $18 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $17 |
| AstraZeneca Pharmaceuticals LP | 1 | $16 |
| PFIZER INC. | 1 | $15 |
Products named: XIFAXAN, OPSUMIT, Ohtuvayre, DUPIXENT, YUPELRI, Adempas, SMARTVEST, GLASSIA.
Industry payments across IN — which companies pay providers there.
